Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | TK2 | O00142 | 1/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL20214217 | 0.94 | TK1 (0.69) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL8023808 | 0.94 | TK1 (0.72) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL993448 | 0.93 | TK1 (0.67) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL14596596 | 0.93 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL767986 | 0.93 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL2722555 | 0.93 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL10382149 | 0.93 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12296879 | 0.93 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL21078835 | 0.93 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL13497202 | 0.93 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777023-B2 | Method for the chemical synthesis of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-6995259-B1 | Method for the chemical synthesis of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2006-02-07 | — | — | US | claimed |
| EP-1401852-B1 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-1401852-A4 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060041115-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | ISIS PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1401852-A2 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030069410-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | ISIS PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002102815-A2 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-1994001446-A2 | DERIVATIZED ORGANIC SOLID SUPPORT FOR NUCLEIC ACID SYNTHESIS | BECKMAN INSTRUMENTS, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| US-4812512-A | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES | ROUSSEL UCLAF (FR) | 1989-03-14 | — | — | US | disclosed |
| US-4780504-A | POLYLACTAMS LINKED TO SILICA MICROPELLETS | ROUSSEL UCLAF (FR) | 1988-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041115-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | RNGTT, NUDT1, NSUN2 | TK1 151/4885LMNA 612/4885SMN1; SMN2 863/4885 |
| US-20030069410-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | RNGTT, TYMP, POLN | TK1 97/4885LMNA 650/4885SMN1; SMN2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.